CHEK2 mutation	Tongue Carcinoma	CHEK2 mutation	Tongue Carcinoma	ABT-888 + M6620 Sensitive: C4 – Case Studies ABT-888 + M6620 Sensitive : C4	ABT-888 + M6620 Sensitive: C4 – Case Studies ABT-888 + M6620 Sensitive : C4
FGFR2 P253R	Tongue Carcinoma	FGFR2 P253R	Tongue Carcinoma	cetuximab Sensitive: C4 – Case Studies cetuximab Sensitive : C4	cetuximab Sensitive: C4 – Case Studies cetuximab Sensitive : C4
FGFR2 P253R	Tongue Carcinoma	FGFR2 P253R	Tongue Carcinoma	pazopanib Sensitive: C4 – Case Studies pazopanib Sensitive : C4	pazopanib Sensitive: C4 – Case Studies pazopanib Sensitive : C4
EGFR wild-type	Tongue Carcinoma	EGFR wild-type	Tongue Carcinoma	osimertinib Sensitive: C4 – Case Studies osimertinib Sensitive : C4	osimertinib Sensitive: C4 – Case Studies osimertinib Sensitive : C4
EGF expression	Tongue Carcinoma	EGF expression	Tongue Carcinoma	cetuximab Resistant: D – Preclinical cetuximab Resistant : D	cetuximab Resistant: D – Preclinical cetuximab Resistant : D

Tongue Carcinoma

Associations(5)